|
FDA Grants Cladribine Priority Review
Merck KGaA said U.S. regulators granted the cladribine multiple sclerosis pill priority review, reducing to six months from 10 the time it will take the FDA to decide on approval.
Bloomberg |
|
FDA Grants Cladribine Priority Review
Merck KGaA said U.S. regulators granted the cladribine multiple sclerosis pill priority review, reducing to six months from 10 the time it will take the FDA to decide on approval.
Bloomberg |
Register Now
Archives